In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Ivabradine and heart failure: experience from a real practice

Session Poster session 3

Speaker Lilyana Mircheva

Congress : Heart Failure 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session
  • FP Number : P1680

Authors : L Mircheva (Varna,BG), YY Yotov (Varna,BG), YB Bocheva (Varna,BG)

15 views

Authors:
L Mircheva1 , YY Yotov1 , YB Bocheva2 , 1Medical University of Varna - Varna - Bulgaria , 2University Hospital St. Marina, Clinical Laboratory, UMHAT St. Marina, Varna, Bulgaria - Varna - Bulgaria ,

Citation:
European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 406

Introduction: Chronic heart failure (CHF) is the most common diagnosis at admission in patients above 65 years. The introduction of ivabradine as a new medication is expected to cope with HF.

Aim: To assess the effect of ivabradine (Iv) after 6 months in patients with CHF NYHA class III-IV post hospitallization.

Materials: We followed 180 patients with CHF for 6 months in an out-patient program. Of them, 80 were in sinus rhythm (SR). The baseline and 6 months levels of NTproBNP, ejection fraction (EF), 6 min walking test (6MWT), NYHA functional class, and renal function were evaluated.

Results: Iv was initiated in 40.3% of patients with SR. After 6 months, the 6MWT improvedt (62.5 m in the Iv vs 23.5 m in the non-Iv group; p=0.043), NTproBNP reduced with median 680 pg/ml and 552,5 pg/ml (p=NS), respectively, and EF increased in Iv with 4.02% and decreased with 1.14% in non-Iv, p=0.06. After 6 months, 77% of the Iv patients were in class II, whereas only 45% of the controls were in class I-II (p=0.023).

Conclusions: Ivabradine in CHF leads to subjective improvement, increases the systolic function, improves the quality of life and functional NYHA class.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are